Kymera Therapeutics, Inc. (KYMR)

NASDAQ: KYMR · Real-Time Price · USD

81.32

-1.81 (-2.18%)

Dec 26, 2025, 4:00 PM EST - Market closed

Kymera Therapeutics Employees

Kymera Therapeutics had 188 employees as of December 31, 2024. The number of employees increased by 1 or 0.53% compared to the previous year.

Employees

188

Change (1Y)

1

Growth (1Y)

0.53%

Revenue / Employee

$232,633

Profits / Employee

-$1,569,798

Market Cap

6.51B

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	188	1	0.53%
Dec 31, 2023	187	20	11.98%
Dec 31, 2022	167	26	18.44%
Dec 31, 2021	141	66	88.00%
Dec 31, 2020	75	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

KYMR News

15 days ago - Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
18 days ago - Kymera Therapeutics Announces Proposed Public Offering - GlobeNewsWire
18 days ago - This Drugmaker's Stock Is Soaring Over 40% Monday - Investopedia
18 days ago - Kymera Therapeutics, Inc. (KYMR) Discusses KT-621 BroADen Phase 1b Results in Atopic Dermatitis Transcript - Seeking Alpha
18 days ago - Kymera's KT-621 Shines: Phase 1b Data Boosts Momentum - Seeking Alpha
18 days ago - Kymera Therapeutics Stock Soars 30%. Why Investors Are Excited About Its Anti-Inflammatory Drug. - Barrons
18 days ago - Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis - GlobeNewsWire
21 days ago - Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025 - GlobeNewsWire